In the first three quarters, the net profit growth rate of the six pharmaceutical companies exceeded 1000%

According to statistics, as of now, more than 90 A-share pharmaceutical companies have disclosed their performance in the first three quarters of 2021, and nearly 70% of the companies are pre-happy
.
From the perspective of companies with outstanding performance, six companies including Mindray Medical, Hengrui Pharmaceutical, Pien Tze Huang, Sinopharm, Sinopharm Accord, Ingram Medical, and Lanfan Medical are expected to exceed 3 billion yuan in net profits in the first three quarters
.
In addition, 26 companies including Northeast Pharmaceutical, Harbin Sanlian, Zuoli Pharmaceutical, Qizheng Tibetan Medicine, and Huaren Pharmaceutical have doubled their net profit.
Harbin Sanlian, Donge Ejiao, Northeast Pharmaceutical and Jiaying Pharmaceutical
.
Yan'an Bikang: The upper limit of net profit growth is 4599.
10% year-on-year.
Yan'an Bikang issued a third-quarter forecast on August 26.
In the first three quarters of this year, the company is expected to achieve a net profit of 550 million yuan to 600 million yuan, compared with 12.
7684 million yuan in the same period last year, a large year-on-year increase.
Increased 4207.
51% to 4599.
10%
.
As for the operating performance of the first three quarters of this year, Yan’an Bikang explained that the company’s new energy products have been affected by market demand, the release of production capacity, and the increase in market prices have contributed to the company’s performance growth.
To actively promote the role
.
In addition, due to the release of production capacity and other reasons, the profit of the new materials sector also increased compared with the same period last year
.
Tai'antang: the upper limit of year-on-year growth in net profit is 1380.
44%.
On October 13, Tai'antang disclosed its performance forecast for the first three quarters of 2021.
The company expects the net profit attributable to shareholders of listed companies in the first three quarters to be 550 million to 600 million yuan, a year-on-year increase of 1257.
07 % To 1380.
44%
.
Harbin Sanlian: the upper limit of year-on-year increase in net profit is 2354.
87%.
Harbin Sanlian issued a performance forecast on the evening of October 13.
During the reporting period, the company is expected to earn 535 million to 544 million yuan, a year-on-year increase of 2314.
25% to 2354.
87%
.
The company attributed the performance change to: the company’s January-September performance of 2021 increased compared to the same period of the previous year, mainly due to the impact of non-recurring gains and losses, mainly due to the company’s 100% equity in Beixing Pharmaceutical, a wholly-owned subsidiary Foreign investment, the impact of this transaction on the company's 2021 consolidated statement level profit and loss amount is approximately 566 million yuan
.
Dong-e-Ejiao: the upper limit of net profit growth is 1608% year-on-year.
On the evening of October 14th, Dong-e-Ejiao released its first three quarters of 2021 performance forecast.
%-1608%
.
It is understood that the reason for the change in performance is the company's insistence on focusing on consumers, firm digital transformation, focusing on customer operations, strengthening brand drive, enriching product matrix, improving organizational effectiveness, and releasing growth potential
.
Northeast Pharmaceutical: Net profit growth cap of 3,595.
04% year-on-year On October 13, Northeast Pharmaceutical disclosed its performance forecast for the first three quarters of 2021.
It is expected to achieve net profit attributable to shareholders of listed companies from January to September 2021 at 24 million to 30 million yuan.
A year-on-year increase of 2856.
03%-3595.
04%
.
During the reporting period, the company actively carried out sales business and formulated differentiated marketing strategies to effectively enhance product competitiveness.
At the same time, the company continued to strengthen corporate management, using various measures such as structural adjustment, technological research, process optimization, cost reduction and efficiency enhancement, etc.
Quantify the refined management to each position, so that the benefits can be fully reflected in the supply, production, and sales links, and the company's sound development can be realized
.
Jiaying Pharmaceutical: Net profit growth ceiling of 2284.
83% year-on-year Jiaying Pharmaceutical released a performance forecast on October 14.
It is expected that the net profit attributable to shareholders of listed companies from January to September 2021 will be 3.
5700 million to 5.
5320 million, a year-on-year change of 1509.
95% to 2284.
83%
.
The company made the above prediction based on the following reasons: the company will be greatly affected by the epidemic in 2020, and its performance will be at a loss
.
The company's production and operation in the first three quarters of 2021 were normal, sales revenue increased year-on-year, and net profit turned from loss to profit year-on-year
.